Supportive Care in Cancer

, Volume 12, Issue 11, pp 762–766 | Cite as

Addition of a second opioid may improve opioid response in cancer pain: preliminary data

  • Sebastiano Mercadante
  • Patrizia Villari
  • Patrizia Ferrera
  • Alessandra Casuccio
Original Article


Recent experimental data suggest a possible use of an opioid combination to improve analgesia. In cancer patients, a rapid opioid escalation due to either worsening of the pain condition or the development of tolerance is a critical phase, as this condition is associated with a negative prognosis. The aim of this study was to assess the effects of adding a second opioid at low doses in patients with a poor analgesic benefit after dose escalation. Fourteen patients receiving strong opioids who had increased their dosage more than 100% in the last week unsuccessfully were randomly chosen to add a second opioid to the first using an initial equivalent dosage of 20% of the previous therapy. The dose of the second opioid was then changed according to the clinical situation to obtain an acceptable pain control with minimal adverse effects. Pain and symptoms associated with opioid therapy were assessed, and an opioid escalation index (OEI) was calculated at weekly intervals. OEI significantly decreased after adding the second opioid, and this trend was also maintained for the following weeks. Similarly, pain intensity was significantly improved and maintained at acceptable levels for the following weeks. The second opioid did not induce significant opioid-related adverse effects. The opioid combination was able to break opioid escalation in patients with pain syndromes with a poor response to the previous opioid. It allowed for a regaining of analgesia, regardless of the opioid combination used. These preliminary observations should be confirmed in further studies.


Cancer pain Opioids Tolerance Switching 


  1. 1.
    Anderson R, Saiers JH, Abram S, Schlicht C (2001) Accuracy in equianalgesic dosing: conversion dilemmas. J Pain Symptom Manage 21:397–406PubMedGoogle Scholar
  2. 2.
    Bruera E, MacMillan D, Hanson J, MacDonald RN (1989) The Edmonton staging system for cancer pain: preliminary report. Pain 37:203–210CrossRefPubMedGoogle Scholar
  3. 3.
    Daeninck PJ, Bruera E (1999) Opioid use in cancer pain. Is a more liberal approach enhancing toxicity? Acta Anaesthesiol Scand 43:924–938PubMedGoogle Scholar
  4. 4.
    de Stouz ND, Bruera E, Suarez-Alamzor M (1995) Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 10:378–384PubMedGoogle Scholar
  5. 5.
    Donner B, Zenz M, Tryba M, Strumpf M (1996) Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain 64:527–5347CrossRefPubMedGoogle Scholar
  6. 6 .
    Eisinger DA, Ammer H, Schulz R (2002) Chronic morphine treatment inhibits opioid receptor desensitization and internalization. J Neurosci 22:10192–10200PubMedGoogle Scholar
  7. 7.
    Gourlay GK, Cherry DA, Cousins MJ (1986) A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. Pain 25:297–312CrossRefPubMedGoogle Scholar
  8. 8.
    He L, Fong J, von Zastrow M, Whistler JL (2002) Regulation of opioid receptor trafficking and morphine tolerance by receptor oligomerization. Cell 108:271–282PubMedGoogle Scholar
  9. 9.
    Mao J, Price DD, Mayer DJ (1995) Mechanisms of hyperalgesia and opioid tolerance: a current view of their possible interactions. Pain 62:259–274CrossRefPubMedGoogle Scholar
  10. 10.
    Mao J (2002) Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy. Pain 100:213–218, 2002CrossRefPubMedGoogle Scholar
  11. 11.
    Mercadante S (1999) Opioid rotation for cancer pain: rationale and clinical aspects. Cancer 86:1856–1866CrossRefPubMedGoogle Scholar
  12. 12.
    Mercadante S (2001) The need for opioid dose escalation: differential diagnosis and management strategies. In “Topics in palliative care”. Portenoy & Bruera, eds, Oxford University Press, New York, pp 213–246Google Scholar
  13. 13.
    Mercadante S, Portenoy RK (2001) Opioid poorly responsive cancer pain. Part 2. Basic mechanisms that could shift dose-response for analgesia. J Pain Symptom Manage 21:255–264Google Scholar
  14. 14.
    Mercadante S, Casuccio A, Calderone L (1999) Rapid switching from morphine to methadone in cancer patients with poor response to morphine. J Clin Oncol 17:3307–3312PubMedGoogle Scholar
  15. 15.
    Mercadante S. Fulfaro F, Casuccio A, Agnello A, Barresi L (1999) Investigation on an opioid response categorization in advanced cancer patients. J Pain Symptom Manage 18:347–352Google Scholar
  16. 16.
    Mercadante S, Ferrera P, Villari P, Arcuri E (2003) Hyperalgesia: an emerging iatrogenic syndrome. J Pain Symptom Manage 26:769–775Google Scholar
  17. 17.
    Portenoy RK (1995) Tolerance to opioid analgesics: clinical aspects. Cancer Surveys 21:49–65Google Scholar
  18. 18.
    Ross FB, Wallis SC, Smith MT (2000) Co-administration of sub-antinociceptive doses of oxycodone and morphine produces marked antinociceptive synergy with reduced SNC side effects in rats. Pain 84:421–428PubMedGoogle Scholar
  19. 19.
    Sjogren P, Jensen NH, Jensen TS (1994) Disappearance of morphine-induced hyperalgesia after discontinuing or substituting with other opioid agonists. Pain 59:313–316CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Sebastiano Mercadante
    • 1
    • 3
  • Patrizia Villari
    • 1
  • Patrizia Ferrera
    • 1
  • Alessandra Casuccio
    • 1
    • 2
  1. 1.Anesthesia and Intensive Care Unit and Pain Relief and Palliative Care Unit, La Maddalena Cancer Center, Palliative MedicineChair of Anesthesia, Intensive Care and EmergencyPalermoItaly
  2. 2.Department of Hygiene and MicrobiologyUniversity of PalermoPalermoItaly
  3. 3.PalermoItaly

Personalised recommendations